JP2015520175A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015520175A5 JP2015520175A5 JP2015515352A JP2015515352A JP2015520175A5 JP 2015520175 A5 JP2015520175 A5 JP 2015520175A5 JP 2015515352 A JP2015515352 A JP 2015515352A JP 2015515352 A JP2015515352 A JP 2015515352A JP 2015520175 A5 JP2015520175 A5 JP 2015520175A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- antagonist
- polynucleotide
- subject
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000427 antigen Substances 0.000 claims 40
- 102000036639 antigens Human genes 0.000 claims 40
- 108091007433 antigens Proteins 0.000 claims 39
- 239000003814 drug Substances 0.000 claims 30
- 102000040430 polynucleotide Human genes 0.000 claims 23
- 108091033319 polynucleotide Proteins 0.000 claims 23
- 239000002157 polynucleotide Substances 0.000 claims 23
- 102000010787 Interleukin-4 Receptors Human genes 0.000 claims 21
- 108010038486 Interleukin-4 Receptors Proteins 0.000 claims 21
- 241000700605 Viruses Species 0.000 claims 17
- 239000005557 antagonist Substances 0.000 claims 17
- 229940079593 drug Drugs 0.000 claims 17
- 239000003795 chemical substances by application Substances 0.000 claims 10
- 230000035772 mutation Effects 0.000 claims 8
- 230000037430 deletion Effects 0.000 claims 6
- 238000012217 deletion Methods 0.000 claims 6
- 241000725303 Human immunodeficiency virus Species 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- 108090000978 Interleukin-4 Proteins 0.000 claims 4
- 230000002238 attenuated effect Effects 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- 101710177291 Gag polyprotein Proteins 0.000 claims 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims 3
- 108010078428 env Gene Products Proteins 0.000 claims 3
- 210000002865 immune cell Anatomy 0.000 claims 3
- 208000015181 infectious disease Diseases 0.000 claims 3
- 108010089520 pol Gene Products Proteins 0.000 claims 3
- 230000037452 priming Effects 0.000 claims 3
- 241000178270 Canarypox virus Species 0.000 claims 2
- 241000700662 Fowlpox virus Species 0.000 claims 2
- 101001002709 Homo sapiens Interleukin-4 Proteins 0.000 claims 2
- 229940123418 Interleukin 4 receptor antagonist Drugs 0.000 claims 2
- 102000012347 Interleukin-4 Receptor alpha Subunit Human genes 0.000 claims 2
- 108010061858 Interleukin-4 Receptor alpha Subunit Proteins 0.000 claims 2
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 2
- 241000700618 Vaccinia virus Species 0.000 claims 2
- 206010046865 Vaccinia virus infection Diseases 0.000 claims 2
- 230000000890 antigenic effect Effects 0.000 claims 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims 2
- 230000000903 blocking effect Effects 0.000 claims 2
- 102000055229 human IL4 Human genes 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 230000011664 signaling Effects 0.000 claims 2
- 241000701161 unidentified adenovirus Species 0.000 claims 2
- 208000007089 vaccinia Diseases 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- 108010083359 Antigen Receptors Proteins 0.000 claims 1
- 238000001647 drug administration Methods 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 230000001052 transient effect Effects 0.000 claims 1
- 238000002255 vaccination Methods 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2012902345A AU2012902345A0 (en) | 2012-06-05 | Vaccination with Interleukin-4 Antagonists | |
| AU2012902345 | 2012-06-05 | ||
| PCT/AU2013/000589 WO2013181696A1 (en) | 2012-06-05 | 2013-06-05 | Vaccination with interleukin-4 antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015520175A JP2015520175A (ja) | 2015-07-16 |
| JP2015520175A5 true JP2015520175A5 (enExample) | 2016-07-21 |
Family
ID=49711200
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015515352A Pending JP2015520175A (ja) | 2012-06-05 | 2013-06-05 | インターロイキン−４アンタゴニストを伴うワクチン接種 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20150150963A1 (enExample) |
| EP (2) | EP3530283A1 (enExample) |
| JP (1) | JP2015520175A (enExample) |
| KR (1) | KR20150021088A (enExample) |
| CN (1) | CN104717971A (enExample) |
| AU (1) | AU2013271338B2 (enExample) |
| BR (1) | BR112014030436A2 (enExample) |
| CA (1) | CA2875683A1 (enExample) |
| HK (1) | HK1203358A1 (enExample) |
| IL (1) | IL236092A0 (enExample) |
| IN (1) | IN2014DN10408A (enExample) |
| NZ (1) | NZ702721A (enExample) |
| SG (1) | SG11201408101TA (enExample) |
| WO (1) | WO2013181696A1 (enExample) |
| ZA (1) | ZA201409076B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017220184B2 (en) * | 2016-02-19 | 2024-04-18 | Regeneron Pharmaceuticals, Inc. | Methods for enhancing efficacy of a vaccine by administering an IL-4R antagonist |
| CN113527485B (zh) | 2020-04-17 | 2024-11-15 | 湖南麦济生物技术股份有限公司 | 抗人白细胞介素-4受体α抗体及其制备方法和应用 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5505941A (en) | 1981-12-24 | 1996-04-09 | Health Research, Inc. | Recombinant avipox virus and method to induce an immune response |
| US7045313B1 (en) | 1982-11-30 | 2006-05-16 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| HU212924B (en) | 1989-05-25 | 1996-12-30 | Chiron Corp | Adjuvant formulation comprising a submicron oil droplet emulsion |
| MY109299A (en) | 1990-08-15 | 1996-12-31 | Virogenetics Corp | Recombinant pox virus encoding flaviviral structural proteins |
| US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| JP3282188B2 (ja) | 1991-06-27 | 2002-05-13 | 日本電気株式会社 | 半導体メモリ装置 |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| US5871742A (en) | 1993-03-31 | 1999-02-16 | Nippon Zeon Co., Ltd | Recombinant Avipox virus encoding polypeptide of mycoplasma gallisepticum, and utilized a live vaccine |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| DE69529495T2 (de) | 1994-01-21 | 2003-06-12 | Powderject Vaccines, Inc. | Gasbetätigtes element zum austragen von genmaterial |
| GB9502879D0 (en) | 1995-02-14 | 1995-04-05 | Oxford Biosciences Ltd | Particle delivery |
| US6265387B1 (en) | 1995-10-11 | 2001-07-24 | Mirus, Inc. | Process of delivering naked DNA into a hepatocyte via bile duct |
| US6458560B1 (en) | 1996-04-05 | 2002-10-01 | Chiron Corporation | Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis |
| US6451592B1 (en) | 1996-04-05 | 2002-09-17 | Chiron Corporation | Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis |
| JP2000514290A (ja) | 1996-07-01 | 2000-10-31 | ローヌ―プーラン・ロレ・エス・アー | 組換えアデノウイルスの製造方法 |
| US5993412A (en) | 1997-05-19 | 1999-11-30 | Bioject, Inc. | Injection apparatus |
| EP1042494A1 (en) | 1997-12-23 | 2000-10-11 | Introgene B.V. | Adeno-associated virus and adenovirus chimeric recombinant viruses useful for the integration of foreign genetic information into the chromosomal dna of target cells |
| US7922709B2 (en) | 1998-07-13 | 2011-04-12 | Genetronics, Inc. | Enhanced delivery of naked DNA to skin by non-invasive in vivo electroporation |
| US6972013B1 (en) | 1998-07-13 | 2005-12-06 | Genetronics, Inc. | Enhanced delivery of naked DNA to skin by non-invasive in vivo electroporation |
| US7608273B2 (en) | 1998-08-12 | 2009-10-27 | University Of Western Ontario | Recombinant lentivirus encoding modified GP 120 signal sequences |
| AT408615B (de) | 1998-09-15 | 2002-01-25 | Immuno Ag | Neue influenzavirus-impfstoffzusammensetzung |
| JP4693244B2 (ja) | 1999-03-18 | 2011-06-01 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 組換えアデノ随伴ウイルスのヘルパー無しの生産のための組成物および方法 |
| ATE528406T1 (de) | 1999-04-29 | 2011-10-15 | Gbp Ip Llc | Verfahren und mittel zur herstellung von sicheren,rekombinanten lentivirusvektoren mit hohem titer |
| GB9923176D0 (en) | 1999-09-30 | 1999-12-01 | Smithkline Beecham Biolog | Novel composition |
| AU2001257611A1 (en) | 2000-04-28 | 2001-11-12 | Avigen, Inc. | Polynucleotides for use in recombinant adeno-associated virus virion production |
| MXPA04011194A (es) | 2002-05-16 | 2005-02-14 | Bavarian Nordic As | Virus de viruela recombinantes que expresan los genes homologos introducidos dentro del genoma viral de la viruela. |
| WO2004028563A1 (en) | 2002-09-27 | 2004-04-08 | Genexine Inc. | A vaccine enhancing the protective immunity to hepatitis c virus using plasmid dna and recombinant adenovirus |
| WO2007121194A1 (en) * | 2006-04-10 | 2007-10-25 | The Regents Of The University Of California | Immunostimulatory recombinant intracellular pathogen immunogenic compositions and methods of use |
| WO2006012221A2 (en) | 2004-06-25 | 2006-02-02 | The Regents Of The University Of California | Target cell-specific short interfering rna and methods of use thereof |
| WO2006135436A2 (en) | 2004-10-22 | 2006-12-21 | University Of Florida Research Foundation, Inc. | Inhibition of gene expression and therapeutic uses thereof |
| US7611690B2 (en) | 2005-01-04 | 2009-11-03 | Gp Medical, Inc. | Nanoparticles for protein drug delivery |
| US8048404B1 (en) | 2005-01-04 | 2011-11-01 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles for protein drug delivery |
| US7541046B1 (en) | 2005-01-04 | 2009-06-02 | Gp Medical, Inc. | Nanoparticles for protein drug delivery |
| US8124398B2 (en) | 2005-04-24 | 2012-02-28 | Sanofi Pasteur Biologics Co. | Recombinant flavivirus vaccines |
| AR054822A1 (es) | 2005-07-07 | 2007-07-18 | Sanofi Pasteur | Emulsion inmuno adyuvante |
| MX2008008968A (es) * | 2006-01-11 | 2008-09-10 | Aerovance Inc | Metodos y composiciones para tratar asma en primates humanos y no humanos. |
| AR066240A1 (es) * | 2007-04-23 | 2009-08-05 | Wyeth Corp | Metodos y composiciones para tratar y monitorear el tratamiento de trastornos asociados con il-13 |
| US20120088814A1 (en) * | 2009-03-31 | 2012-04-12 | Isis Pharmaceuticals, Inc. | Methods of modulating an immune response to a viral infection |
| US20120177668A1 (en) * | 2009-07-06 | 2012-07-12 | The Australian National University | Immunomodulating compositions comprising interleukin 13 inhibitors and uses therefor |
-
2013
- 2013-06-05 KR KR20147037109A patent/KR20150021088A/ko not_active Withdrawn
- 2013-06-05 SG SG11201408101TA patent/SG11201408101TA/en unknown
- 2013-06-05 HK HK15103819.6A patent/HK1203358A1/xx unknown
- 2013-06-05 CA CA2875683A patent/CA2875683A1/en not_active Abandoned
- 2013-06-05 IN IN10408DEN2014 patent/IN2014DN10408A/en unknown
- 2013-06-05 CN CN201380040156.6A patent/CN104717971A/zh active Pending
- 2013-06-05 BR BR112014030436A patent/BR112014030436A2/pt not_active IP Right Cessation
- 2013-06-05 EP EP19150395.2A patent/EP3530283A1/en not_active Withdrawn
- 2013-06-05 AU AU2013271338A patent/AU2013271338B2/en not_active Ceased
- 2013-06-05 WO PCT/AU2013/000589 patent/WO2013181696A1/en not_active Ceased
- 2013-06-05 US US14/405,704 patent/US20150150963A1/en not_active Abandoned
- 2013-06-05 JP JP2015515352A patent/JP2015520175A/ja active Pending
- 2013-06-05 NZ NZ702721A patent/NZ702721A/en not_active IP Right Cessation
- 2013-06-05 EP EP13800233.2A patent/EP2854837A4/en not_active Withdrawn
-
2014
- 2014-12-04 IL IL236092A patent/IL236092A0/en unknown
- 2014-12-10 ZA ZA2014/09076A patent/ZA201409076B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7244462B2 (ja) | ネオ抗原ワクチンによる併用療法 | |
| Ewer et al. | A monovalent chimpanzee adenovirus Ebola vaccine boosted with MVA | |
| García-Martínez et al. | Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy | |
| Sun et al. | Mucosal priming with a replicating-vaccinia virus-based vaccine elicits protective immunity to simian immunodeficiency virus challenge in rhesus monkeys | |
| RU2015155821A (ru) | Вакцины против малярии | |
| JP2020528911A5 (enExample) | ||
| JP2019526580A5 (enExample) | ||
| JP2016527286A5 (enExample) | ||
| JP2016074727A5 (enExample) | ||
| JP2015506179A5 (enExample) | ||
| BR112018068748A2 (pt) | composto, composição farmacêutica e de vacina, métodos para indução ou promoção de uma resposta imunológica, para tratamento de câncer, de doenças infecciosas, de distúrbios imunológicos e de doenças imunológicas e para tratamento ou prevenção de uma doença, e, uso de um composto | |
| PH12018502684B1 (en) | A rationally developed african swine fever attenuated virus strain protects against challenge with parental virus georgia 2007 isolate | |
| RU2015132962A (ru) | Иммуногенные композиции на основе вируса гриппа и их применение | |
| JP2016516723A5 (enExample) | ||
| JP2017523187A5 (enExample) | ||
| JP2017501695A5 (enExample) | ||
| JP2015529676A5 (enExample) | ||
| CN111655281A (zh) | 用于结核病的含环二核苷酸佐剂的疫苗的鼻内递送 | |
| JP2015512866A5 (enExample) | ||
| JP2012087150A5 (enExample) | ||
| JP2015533376A5 (enExample) | ||
| JP2011041578A5 (enExample) | ||
| JP2017538680A5 (enExample) | ||
| JP2015514132A5 (enExample) | ||
| BR112016013804A2 (pt) | imunoterapia de câncer distribuindo antígenos mhc de classe ii usando um replicon de vlp |